ELPENHALER^®, is ELPEN's proprietary Dry Powder Inhaler (DPI) device, developed for the uptake of powdered medication(s) via inhalation, invented by Dimitrios Pentafragas, our Chairman, CEO.

The active ingredients are packed in specially designed single-dose alu-alu blister strips.

The device was initially developed for the administration of anti-asthma and COPD medications, but it can also be used for the administration of any medication suitable for lung delivery in the treatment of pulmonary diseases.

ELPENHALER^® is breath-activated and presents many advantages to the user, such as a robust construction, accurate dosing, it is user-friendly, but most importantly, visual verification of drug uptake is feasible, a novelty for dry powder inhaler devices.

As of  today, ELPEN has developed and offers three anti-asthma / COPD products using the ELPENHALER^®  device:

• Formopen^® (formoterol) generic to Foradil^®/Novartis, marketed since 2007
  
• Fluticapen^® (fluticasone) generic to Flixotide^®/ Diskus^®/GSK, marketed since  2008
  
• Rolenium^®(fluticasone/salmeterol) generic to Seretide^® Diskus^®/GSK, launched in Greece in November 2009 (the product has achieved a 12% market share in the Greek ICS (inhaled corticosteroids)+LABA (long-acting beta adrenoreceptor agonist) market, and approximately 36% of the Seretide^® Diskus^® sales (MAT M07/2011). 
  
  
  

In May 2011, Rolenium^® was approved in seven (7) European countries (Sweden, Germany, Italy, Portugal, Czech Republic, Hungary and Slovakia) through the Decentralised Procedure (DCP).

Rolenium^®, is the first generic fluticasone + salmeterol combination product approved in Europe, a substantial achievement of which we are very proud!